ProMedView and RAIsonance have teamed up to bring you cutting edge technology designed to preserve the workforce and reduce medical spend by:

1. Providing early warnings when the status of the respiratory system is impacted by illness, disease, or environmental exposures.

2. Supporting users in Long COVID recovery.

3. Supporting users in quitting smoking or vaping.

4. Supporting users in managing chronic health conditions such as COPD and CHF.

Note: These products are also available for consumers. Ask about our individual and family pricing.

Neuro COVID is a subcategory of post COVID complications affecting the brain and nervous system. Antibody studies show this occurs in about 40% of those experiencing post viral syndrome.

It appears the newest COVID-19 variants have the ability to slip by the antibody response people have built from prior infections and the vaccination. This means everyone is vulnerable, and the risks of neuro COVID, organ failure, hospitalizations, and death are higher.

Although we have passed the emergency phase of the pandemic, COVID will present a continued threat to the workforce and the community as new variants become more contagious. Research has shown that at least 12%-30% of people infected with COVID will develop Post COVID Condition, or Long COVID. This condition can affect anyone of any age and any health status, regardless of the severity of the infection. Symptoms like brain fog, headache, fatigue, depression and insomnia are caused by neural inflammation, and research shows that repeat infections increase the risk of organ failure, brain damage, and central nervous system dysfunction. For those that have already experienced PCC, repeat infections can be expected to increase symptoms and cellular damage.

In order to preserve the workforce, we need options for early diagnosis and early intervention. ProMedView has proudly partnered with RAIsonance to help you meet the safety, health, & wellness challenges ahead using Forced Cough Vocalization & Innovation in Respiratory Wellness. Learn more here.

A report released by New York State Insurance Fund found that 31% of workers who filed claims for COVID-19 continued medical treatment or took time off work more than 60 days after the initial infection. This article provides insights into the demographics of those affected and the claims outcomes.

It is well documented that inflammation plays a significant role in Post COVID Condition (PCC), aka Long COVID. This article offers insights as to how neuro COVID develops by detailing the pathophysiology in the brain that correlates with post COVID depressive and cognitive symptoms, including slowed motor speed, low motivation or energy, and anhedonia, after initially mild to moderate COVID-19 illness. This information validates the need for early identification of new (acute) infections and post-acute phases to prevent or minimize the risks associated with long term damage that can occur when neural inflammation is left untreated.

Read about how the brain has been impacted by COVID-19 in those experiencing brain fog and other neurological symptoms such as depression, anxiety, seizures, twitching, vibrations, changes in hormones and the senses including smell, taste, hearing, vision and touch. This NIH article discusses the emerging clinical data from the COVID-19 pandemic suggests that ~ 40% of COVID-19 patients develop neurological symptoms attributed to viral encephalitis while in COVID long haulers chronic neuro-inflammation and neuronal damage result in a syndrome described as Neuro-COVID.